• ColoSTAT® progresses to final production validation phase
• ColoSTAT® algorithm successfully validated using clinical samples
• Secured Genetype's first strategic partnership under an initial pilot program

Rhythm Biosciences Ltd (ASX:RHY), a transformative cancer diagnostics technology company, has released its Q4 FY25 business update and Appendix 4C. Key highlights include the ColoSTAT® blood test progressing to the final production validation phase, successful validation of the ColoSTAT® algorithm using clinical samples, and the achievement of defined clinical benchmarks for the test. The company also secured Genetype's first strategic partnership under an initial pilot program, a major milestone for Genetype's commercialization strategy. Rhythm has also reinstated NATA accreditation for Genetype's risk assessment portfolio, advanced the readiness of ColoSTAT® as a NATA-accredited service, and made progress on the commercial study with the University of Melbourne. Financially, the company's FY25 revenue performance aligned with the acquisition model assumptions for Genetype, and it secured $1 million in non-dilutive RDTI funding. The company also announced changes to its Board of Directors, with Non-Executive Chairman Otto Buttula retiring and Gavin Fox-Smith assuming the role of Chairman. Additionally, Rhythm introduced a shareholder benefits discount program for Genetype's multi-risk test kit and plans to offer a similar program for ColoSTAT® upon launch.

Rhythm Biosciences' FY25 revenue performance was well aligned with the acquisition model assumptions for Genetype, underpinning the strategic rationale of the recent acquisition.

Rhythm Biosciences is confident that FY26 will be a transformative year as the company continues to outperform internal expectations and roadmaps and execute on its growth strategy, including the launch of ColoSTAT® and further commercial expansion of the Genetype portfolio.